Sign in
Not yet recruitingNo phase

Daily or every-other-day plasma exchange for children with Wilson disease

Compares plasma exchange schedules in children with Wilson disease liver failure.

Key facts

Who runs it
Institute of Liver and Biliary Sciences, India
Where
India1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children
Status
Not yet recruiting
People taking part
20 people, planned
Started
10 Nov 2024
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Plasma Exchange
  • Standard Medical Treatment
Record updated
21 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children with Wilson disease and acute liver failure. It compares plasma exchange every day with plasma exchange every other day.

Age
3 Years to 18 Years
Sex
All
Disease stage
Wilson disease with acute liver failure, with a New Wilson Index of ≥ 11 and INR ≥ 2.5.
Biomarker or test result
New Wilson Index of ≥ 11 and INR (a blood clotting test) ≥ 2.5.

Main reasons for not taking part

  • Grade 3 or grade 4 hepatic encephalopathy (severe brain problems caused by liver failure)
  • Septic shock (very low blood pressure from a severe infection)
  • Disseminated intravascular coagulation (widespread blood clotting problem)
  • Very unstable blood pressure needing high doses of vasopressors (norepinephrine >0.5 mcg/kg/min)
  • Any severe heart or lung disease from before

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Wilson disease with New Wilson Index of ≥ 11 and INR ≥ 2.5
  • Children aged 3 years to 18 years

Who cannot take part

  • Any severe cardio-pulmonary pre-existing disease
  • Grade 3 or grade 4 hepatic encephalopathy
  • Septic shock
  • Disseminated intravascular coagulation
  • Marked hemodynamic instability requiring a high dose of vasopressors (norepinephrine >0.5 mcg/kg/min)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 3 and 18 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Wilson disease in children has a varied presentation. Wilson disease with acute liver failure is associated with very high mortality and morbidity. The standard therapy i.e chelation (with either D- penicillamine or trientene can be used as a temporizing agent to treat the enormous release of copper into the blood stream; however, substantial removal is not achieved for at least 1 to 3 months. Plasma exchange provides a means of rapid means of removal of copper. As per American Society for Apheresis, TPE in wilson disease with acute liver failure can rapidly remove an average of 20 mg of copper per TPE treatment. Decreased serum copper may decrease hemolysis, prevent progression of kidney failure and provide clinical stabilization. TPE can also remove large molecular weight toxins (aromatic amino acids, ammonia, endotoxins) and other factors, which may be responsible for hepatic coma. The frequency of said TPE is not defined as most evidence is based on case reports and case series.

Read full original descriptionShow less

Copper is highly protein bound and the volume of distribution for copper is large. Under normal conditions, 90-95% of serum copper is ceruloplasmin-bound with the remaining 5-10% being nonceruloplasmin-bound. TPE efficiently removes both ceruloplasmin- and albumin-bound copper. FFP used for exchange can be helpful in treating the associated coagulopathy. TPE has been used as a bridge to liver transplantation as well as seen to improve survival with native liver, the optimum protocol for same remains uncertain.

The 2 groups in the trial

  • Daily plasma exchange + SMTTreatment being tested

    (Maximum 3+1 sessions during a period of 7 days)

    Treatment: Plasma Exchange and Standard Medical Treatment

  • Alternate day therapeutic plasma exchange + SMTExisting treatment, for comparison

    Treatment: Plasma Exchange and Standard Medical Treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children: A Randomized Controlled Trial
Plain-language title
Daily or every-other-day plasma exchange for children with Wilson diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Fit questions
Built from NCT06698991, who can take part
Record updated
21 November 2024